Benedikt Timmerman
Direttore/Membro del Consiglio presso Antabio SAS
Relazioni attive
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Frédéric Chéreau | M | 57 |
Horama SA
 Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 3 anni |
| Marc Lemonnier | M | 57 |
Antabio SAS
 Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | 15 anni |
| Jean-Loup Romet-Lemonne | M | 73 |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | - |
| Gordon Waldron | M | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | - |
| Jérôme Becquart | M | - |
BrainVectis SAS
 BrainVectis SAS BiotechnologyHealth Technology BrainVectis SAS provides gene therapy services. It develops gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain to restore cholesterol metabolism. The company was founded by Nathalie Cartier-Lacave and Jérôme Becquart in 2015 and is headquartered in Paris, France. | 9 anni |
| Helmuth van Es | M | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | 15 anni |
| Olivier Danos | M | 66 |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 3 anni |
| Claudia Mitchell | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 2 anni |
| Nathalie Cartier-Lacave | M | - |
BrainVectis SAS
BrainVectis SAS BiotechnologyHealth Technology BrainVectis SAS provides gene therapy services. It develops gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain to restore cholesterol metabolism. The company was founded by Nathalie Cartier-Lacave and Jérôme Becquart in 2015 and is headquartered in Paris, France. | 9 anni |
| Bervin Bouani | M | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | - |
| Claire Poulard | F | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | - |
| Christophe Ricard | M | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | - |
| Aurelien Chollet | M | - |
Antabio SAS
Antabio SAS Pharmaceuticals: MajorHealth Technology Antabio SAS operates as a biopharmaceutical company which develops drugs for the treatment and prevention of antibiotic-resistant bacterial infections. The firm focuses bacterial disease research, drug design, antibiotic combination testing, and in vitro technology development operations. The company was founded by Marc Lemonnier and Aymeric Dugray on October 15, 2009 and is headquartered in Labege, France. | 9 anni |
| Patricia Françon | M | - |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | 3 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
| Nome | Sesso | Età | Società collegate | Collaborazione |
|---|---|---|---|---|
| Michael Pragnell | M | 77 | 7 anni | |
| John Ramsay | M | 66 | 16 anni | |
| Heinz Imhof | M | - |
Novartis Seeds AG
 Novartis Seeds AG Chemicals: AgriculturalProcess Industries Part of Novartis AG, Novartis Seeds AG is a company that manufactures agro-chemical products. The company is based in Novartis, Switzerland.
Sandoz, Inc.
 Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 11 anni |
| Gavin Hill | M | 56 | 2 anni | |
| Gino van Ossel | M | 59 |
Ghent University
| 6 anni |
| John Atkin | M | 70 | 14 anni | |
| Dirk JS Van den Berghen | M | 61 |
Ghent University
| 6 anni |
| Luc van den Durpel | M | - |
Ghent University
| 4 anni |
| Philip Julien de Cnudde | M | 63 |
Ghent University
| 6 anni |
| Felix Weber | M | 73 | 13 anni | |
| Rolf Urs Watter | M | 66 | 12 anni | |
| Jean-Marie Descarpentries | M | 87 | - | |
| Pierre Landolt | M | 77 | 12 anni | |
| Alexandre F. Jetzer-Chung | M | 83 |
Sandoz, Inc.
Sandoz, Inc. Pharmaceuticals: MajorHealth Technology Sandoz, Inc. develops, manufactures and distributes generic pharmaceutical products. The firm focuses on therapeutic drug categories such as anti-infective, central nervous system disorder treatments, cardiovascular medicines, gastrointestinal agent, oncology therapies, and respiratory therapies. The company was founded in 1946 and is headquartered in Princeton, NJ. | 16 anni |
| Peter M. Thompson | M | 77 | 13 anni | |
| Fernando Musa | M | 58 |
INSEAD
| 2 anni |
| Pascal Kiener | M | 62 |
INSEAD
| 2 anni |
| Alessandro Maria Decio | M | 58 |
INSEAD
| 1 anni |
| Jorge Bento Ribeiro Barbosa Farinha | M | - |
INSEAD
| 2 anni |
| Donald Charles McQueen | M | 62 |
INSEAD
| 2 anni |
| Jan Derck van Karnebeek | M | 57 |
INSEAD
| 2 anni |
| Christel Elise Borge | F | 57 |
INSEAD
| 2 anni |
| Neil C. McArthur | M | 63 |
INSEAD
| 2 anni |
| Bruno Duarte | M | 58 |
INSEAD
| 4 anni |
| Andrew Edward Anson | M | 59 |
INSEAD
| 2 anni |
| Adolfo Carvajal Isla | M | - |
INSEAD
| - |
| Francisco Ravara Cary | M | 58 |
INSEAD
| 2 anni |
| Nicolas Martin | M | - |
INSEAD
| 2 anni |
| Mario Reis | M | 64 |
INSEAD
| 1 anni |
| Francois-Alfred-Mari Pinchon | M | 72 |
INSEAD
| 4 anni |
| Troels Bugge Henriksen | M | 60 |
INSEAD
| 2 anni |
| Fabrice Desmarescaux | M | - |
INSEAD
| 1 anni |
| Yuji Ito | M | 60 |
INSEAD
| 2 anni |
| Kate Philips | F | - |
INSEAD
| 4 anni |
| Simon Griffiths | M | - |
INSEAD
| - |
| Vasileios Koutentakis | M | 61 |
INSEAD
| 2 anni |
| Enrica Acuto Jacobacci | F | - |
INSEAD
| 3 anni |
| Olivier Baldassari | M | - |
INSEAD
| 2 anni |
| Christina Law | F | 57 |
INSEAD
| 2 anni |
| Didier Marginedès | M | 69 |
INSEAD
| 2 anni |
| Enrico Berton | M | 58 |
INSEAD
| 1 anni |
| Jean-Marc Etlin | M | - |
INSEAD
| 1 anni |
| Jan Robin Waaler | M | 73 |
INSEAD
| 2 anni |
| Diogo Francisco Bastos Mendes Rezende | M | 57 |
INSEAD
| 1 anni |
| Anna Elisabet Nyquist | F | 62 |
INSEAD
| 2 anni |
| Minter Dial | M | 59 |
INSEAD
| 2 anni |
| Susanne Wamsler | F | 63 |
INSEAD
| 2 anni |
| Renier Lemmens | M | 60 |
INSEAD
| 2 anni |
| Ludovic de Meeus d'Argenteuil | M | - |
INSEAD
| 2 anni |
| Hugues Pitre | M | - |
INSEAD
| 4 anni |
| Timothy Bovard | M | - |
INSEAD
| 2 anni |
| Mika Jerry Salmi | M | 58 |
INSEAD
| 2 anni |
| John Witt | M | 61 |
INSEAD
| 2 anni |
| Ranieri de Marchis | M | 63 |
INSEAD
| 2 anni |
| Roy Merritt | M | 60 |
INSEAD
| - |
| Michael Buhl | M | 65 |
INSEAD
| 2 anni |
| James W. Schubauer | M | - |
INSEAD
| 2 anni |
| Niels Bjørn Christiansen | M | 58 |
INSEAD
| 2 anni |
| André S. Hoffmann | M | 66 |
INSEAD
| 2 anni |
| Bernardo Sanchez Incera | M | 64 |
INSEAD
| 2 anni |
| Jeremy Samuel John Marshall | M | 61 |
INSEAD
| 2 anni |
| Manuel Cubero del Castillo-Olivares | M | 61 |
INSEAD
| 2 anni |
| Diogo António Rodrigues da Silveira | M | 62 |
INSEAD
| 1 anni |
| Francesco Conte | M | - |
INSEAD
| 1 anni |
| Eric I. Steiner | M | 57 |
INSEAD
| 2 anni |
| Anders Hove | M | 58 |
INSEAD
| 1 anni |
| Fausto Boni | M | 59 |
INSEAD
| 2 anni |
| Simon Guild | M | 59 |
INSEAD
| 2 anni |
| Per-Olof Attinger | M | 64 |
INSEAD
| 2 anni |
| Luke Jensen | M | 58 |
INSEAD
| 2 anni |
| Anders B. Christjansen | M | - |
INSEAD
| 2 anni |
| Peter Paul Praxmarer | M | 66 |
INSEAD
| 2 anni |
| Valerio Bellamoli | M | 64 |
INSEAD
| 2 anni |
| Hubert-Lance Huet | M | - |
INSEAD
| 2 anni |
| Axel Bichara | M | 60 |
INSEAD
| 2 anni |
| Fionnuala Clare Duggan | F | 59 |
INSEAD
| 1 anni |
| Georg Stratenwerth | M | 64 |
INSEAD
| 2 anni |
| Corrado Sciolla | M | 61 |
INSEAD
| 2 anni |
| Enrico Petocchi | M | - |
INSEAD
| 1 anni |
| Isidoro Miranda Fernández | M | 65 |
INSEAD
| 2 anni |
| James Patrick Nolan | M | 64 |
INSEAD
| 2 anni |
| Henrik Clausen | M | 61 |
INSEAD
| 2 anni |
| Fritz Mumenthaler | M | 66 |
INSEAD
| 1 anni |
| Christian Hassel | M | 61 |
INSEAD
| 2 anni |
| Philippe Demigné | M | 63 |
INSEAD
| 2 anni |
| Marie-Gabrielle Ineichen-Fleisch | F | 63 |
INSEAD
| 2 anni |
Statistiche
| Paese | Relazioni | % del totale |
|---|---|---|
| Francia | 85 | 85.00% |
| Svizzera | 9 | 9.00% |
| Belgio | 4 | 4.00% |
| Stati Uniti | 2 | 2.00% |
| Lussemburgo | 1 | 1.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Benedikt Timmerman
- Contatti personali
